A Mendelian randomization study of circulating uric acid and type 2 diabetes

Ivonne Sluijs; Michael V. Holmes; Yvonne T. van der Schouw; Joline W. J. Beulens; Folkert W. Asselbergs; José María Huerta; Tom M. Palmer; Larraitz Arriola; Beverley Balkau; Aurelio Barricarte; Heiner Boeing; Françoise Clavel-Chapelon; Guy Fagherazzi; Paul W. Franks; Diana Gavrila; Rudolf Kaaks; Kay Tee Khaw; Tilman Kühn; Esther Molina-Montes; Lotte Maxild Mortensen; Peter M. Nilsson; Kim Overvad; Domenico Palli; Salvatore Panico; J. Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Núria Sala; Julie A. Schmidt; Robert A. Scott; Sabina Sieri; Nadia Slimani; Annemieke Mw Spijkerman; Anne Tjonneland; Ruth C. Travis Dphil; Rosario Tumino; Daphne L. van der A; Stephen J. Sharp; Nita G. Forouhi; Claudia Langenberg; Elio Riboli; Nicholas J. Wareham; InterAct consortium

doi:10.2337/db14-0742

A Mendelian randomization study of circulating uric acid and type 2 diabetes

Ivonne Sluijs, Michael V. Holmes, Yvonne T. van der Schouw, Joline W. J. Beulens, Folkert W. Asselbergs, José María Huerta, Tom M. Palmer, Larraitz Arriola, Beverley Balkau, Aurelio Barricarte, Heiner Boeing, Françoise Clavel-Chapelon, Guy Fagherazzi, Paul W. Franks, Diana Gavrila, Rudolf Kaaks, Kay Tee Khaw, Tilman Kühn, Esther Molina-Montes, Lotte Maxild MortensenPeter M. Nilsson, Kim Overvad, Domenico Palli, Salvatore Panico, J. Ramón Quirós, Olov Rolandsson, Carlotta Sacerdote, Núria Sala, Julie A. Schmidt, Robert A. Scott, Sabina Sieri, Nadia Slimani, Annemieke Mw Spijkerman, Anne Tjonneland, Ruth C. Travis Dphil, Rosario Tumino, Daphne L. van der A, Stephen J. Sharp, Nita G. Forouhi, Claudia Langenberg, Elio Riboli, Nicholas J. Wareham, InterAct consortium

Research output: Contribution to journal › Article (Academic Journal) › peer-review

98 Citations (Scopus)

Abstract

We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. Higher uric acid associated with higher diabetes risk following adjustment for confounders, with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk.

Original language	English
Pages (from-to)	3028-3036
Number of pages	9
Journal	Diabetes
Volume	64
Issue number	8
DOIs	https://doi.org/10.2337/db14-0742
Publication status	Published - Aug 2015

Bibliographical note

This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org/content/64/8/3028

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2337/db14-0742

Handle.net

Persistent link

Cite this

Sluijs, I., Holmes, M. V., van der Schouw, Y. T., Beulens, J. W. J., Asselbergs, F. W., Huerta, J. M., Palmer, T. M., Arriola, L., Balkau, B., Barricarte, A., Boeing, H., Clavel-Chapelon, F., Fagherazzi, G., Franks, P. W., Gavrila, D., Kaaks, R., Khaw, K. T., Kühn, T., Molina-Montes, E., ... consortium, I. (2015). A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes, 64(8), 3028-3036. https://doi.org/10.2337/db14-0742

@article{5744ec56db6c45a79c2c60c7c07b9ad8,

title = "A Mendelian randomization study of circulating uric acid and type 2 diabetes",

abstract = "We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. Higher uric acid associated with higher diabetes risk following adjustment for confounders, with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk.",

author = "Ivonne Sluijs and Holmes, {Michael V.} and {van der Schouw}, {Yvonne T.} and Beulens, {Joline W. J.} and Asselbergs, {Folkert W.} and Huerta, {Jos{\'e} Mar{\'i}a} and Palmer, {Tom M.} and Larraitz Arriola and Beverley Balkau and Aurelio Barricarte and Heiner Boeing and Fran{\c c}oise Clavel-Chapelon and Guy Fagherazzi and Franks, {Paul W.} and Diana Gavrila and Rudolf Kaaks and Khaw, {Kay Tee} and Tilman K{\"u}hn and Esther Molina-Montes and Mortensen, {Lotte Maxild} and Nilsson, {Peter M.} and Kim Overvad and Domenico Palli and Salvatore Panico and Quir{\'o}s, {J. Ram{\'o}n} and Olov Rolandsson and Carlotta Sacerdote and N{\'u}ria Sala and Schmidt, {Julie A.} and Scott, {Robert A.} and Sabina Sieri and Nadia Slimani and Spijkerman, {Annemieke Mw} and Anne Tjonneland and {Travis Dphil}, {Ruth C.} and Rosario Tumino and {van der A}, {Daphne L.} and Sharp, {Stephen J.} and Forouhi, {Nita G.} and Claudia Langenberg and Elio Riboli and Wareham, {Nicholas J.} and InterAct consortium",

note = "This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org/content/64/8/3028",

year = "2015",

month = aug,

doi = "10.2337/db14-0742",

language = "English",

volume = "64",

pages = "3028--3036",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association Inc.",

number = "8",

}

Sluijs, I, Holmes, MV, van der Schouw, YT, Beulens, JWJ, Asselbergs, FW, Huerta, JM, Palmer, TM, Arriola, L, Balkau, B, Barricarte, A, Boeing, H, Clavel-Chapelon, F, Fagherazzi, G, Franks, PW, Gavrila, D, Kaaks, R, Khaw, KT, Kühn, T, Molina-Montes, E, Mortensen, LM, Nilsson, PM, Overvad, K, Palli, D, Panico, S, Quirós, JR, Rolandsson, O, Sacerdote, C, Sala, N, Schmidt, JA, Scott, RA, Sieri, S, Slimani, N, Spijkerman, AM, Tjonneland, A, Travis Dphil, RC, Tumino, R, van der A, DL, Sharp, SJ, Forouhi, NG, Langenberg, C, Riboli, E, Wareham, NJ & consortium, I 2015, 'A Mendelian randomization study of circulating uric acid and type 2 diabetes', Diabetes, vol. 64, no. 8, pp. 3028-3036. https://doi.org/10.2337/db14-0742

TY - JOUR

T1 - A Mendelian randomization study of circulating uric acid and type 2 diabetes

AU - Sluijs, Ivonne

AU - Holmes, Michael V.

AU - van der Schouw, Yvonne T.

AU - Beulens, Joline W. J.

AU - Asselbergs, Folkert W.

AU - Huerta, José María

AU - Palmer, Tom M.

AU - Arriola, Larraitz

AU - Balkau, Beverley

AU - Barricarte, Aurelio

AU - Boeing, Heiner

AU - Clavel-Chapelon, Françoise

AU - Fagherazzi, Guy

AU - Franks, Paul W.

AU - Gavrila, Diana

AU - Kaaks, Rudolf

AU - Khaw, Kay Tee

AU - Kühn, Tilman

AU - Molina-Montes, Esther

AU - Mortensen, Lotte Maxild

AU - Nilsson, Peter M.

AU - Overvad, Kim

AU - Palli, Domenico

AU - Panico, Salvatore

AU - Quirós, J. Ramón

AU - Rolandsson, Olov

AU - Sacerdote, Carlotta

AU - Sala, Núria

AU - Schmidt, Julie A.

AU - Scott, Robert A.

AU - Sieri, Sabina

AU - Slimani, Nadia

AU - Spijkerman, Annemieke Mw

AU - Tjonneland, Anne

AU - Travis Dphil, Ruth C.

AU - Tumino, Rosario

AU - van der A, Daphne L.

AU - Sharp, Stephen J.

AU - Forouhi, Nita G.

AU - Langenberg, Claudia

AU - Riboli, Elio

AU - Wareham, Nicholas J.

AU - consortium, InterAct

N1 - This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org/content/64/8/3028

PY - 2015/8

Y1 - 2015/8

N2 - We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. Higher uric acid associated with higher diabetes risk following adjustment for confounders, with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk.

AB - We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. Higher uric acid associated with higher diabetes risk following adjustment for confounders, with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk.

U2 - 10.2337/db14-0742

DO - 10.2337/db14-0742

M3 - Article (Academic Journal)

C2 - 25918230

SN - 0012-1797

VL - 64

SP - 3028

EP - 3036

JO - Diabetes

JF - Diabetes

IS - 8

ER -

A Mendelian randomization study of circulating uric acid and type 2 diabetes

Abstract

Bibliographical note

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this